Summary: A single dose of psilocybin, the active compound in psychedelic “magic” mushrooms, produced long-lasting reductions in nerve pain in a preclinical mouse model and markedly increased the effectiveness of gabapentin, a commonly prescribed nerve pain medication.
Researchers at the University of Reading report that psilocybin appears to reorganize the brain’s pain-processing networks rather than merely blocking pain signals. This reorganization created sustained pain relief that lasted up to a month in mice and made gabapentin far more effective weeks after the psilocybin dose had cleared from the body.
Key facts
- Long-lasting network reset: A single injection of psilocybin produced anti-pain effects that emerged roughly two hours after dosing and persisted for several weeks. Because the benefit lasted well beyond the drug’s presence in the body, researchers conclude that psilocybin produces durable changes in the brain’s pain-processing circuitry.
- Synergy with gabapentin: The most striking outcome was the interaction with gabapentin. When gabapentin was given weeks after the psilocybin injection—at a time when psilocybin’s direct analgesic effect had worn off—it produced extended relief lasting up to four days. In animals that had not received psilocybin, gabapentin’s effect was far weaker.
- Unmet clinical need: Neuropathic (nerve) pain is difficult to treat; 30–50% of people with this condition fail to achieve adequate relief with gabapentin alone. The new findings point to a potential strategy for improving outcomes without resorting to higher-risk or addictive medications.
- Potential to reduce addiction risk: By priming or resetting pain-processing networks so that established, non-addictive medications work better, psilocybin-based approaches could offer an alternative to opioid or other high-risk treatments.
- Sex-balanced validation: The study confirmed comparable analgesic effects in both male and female mice, addressing a historical sex bias in preclinical pain research.
- Ethical study design: Experiments followed UK Home Office regulations and the 3Rs (Replacement, Reduction, Refinement), minimizing distress and obtaining multiple outcomes per animal to limit numbers used.
Source: University of Reading
Overview
Published in Communications Biology, this preclinical study evaluated the effects of psilocybin in mice with nerve injury that produces long-lasting pain-like behaviors. The investigators tracked both the immediate and longer-term impacts of a single psilocybin injection on pain sensitivity and on the response to gabapentin, a front-line neuropathic analgesic.
Psilocybin’s analgesic effect appeared within a couple of hours after dosing and persisted for weeks. Rather than acting only as an acute blocker of pain signals, the compound seems to induce a functional reorganization of the brain circuits that interpret and amplify pain. That reorganization may explain why a single dose had effects that outlived the compound’s presence in the body.
The interaction with gabapentin was the study’s most important translational observation. When gabapentin was given some weeks after the psilocybin dose—after the direct analgesic benefit from psilocybin had faded—the combination produced analgesia that lasted up to four days. By contrast, gabapentin given without prior psilocybin produced a shorter and weaker effect. This suggests psilocybin can act as a durable “primer” for existing pain medications, enhancing their therapeutic window.
Dr Maria Maiarú, senior author at the University of Reading, emphasized the clinical relevance: many patients with neuropathic pain have limited options, and existing medicines can carry serious side effects or present addiction risks. A treatment that resets pain-processing networks and increases the efficacy of non-addictive drugs could be transformative for people who have exhausted standard therapies.
Key questions answered
A: The study indicates that psilocybin does more than temporarily interrupt pain signaling. Instead, it produces lasting changes in the organization and function of brain networks that process pain, effectively altering how incoming pain signals are interpreted and reducing chronic pain sensitivity for weeks after a single dose.
A: Psilocybin appears to prime the brain’s pain networks so they become more responsive to gabapentin. In the study, animals that received psilocybin weeks earlier experienced substantially enhanced and prolonged analgesia from gabapentin compared with animals that had not received psilocybin, suggesting the psychedelic induced a more receptive neural state for the drug.
A: No. The core point is that a single, isolated administration of psilocybin produced a durable change in pain-related brain circuitry. In a therapeutic model, patients might receive one dose to reset networks, after which standard non-psychedelic medications could provide improved pain control without repeated psychedelic dosing or chronic exposure to addictive drugs.
Editorial notes
- This article was edited by a Neuroscience News editor.
- The full journal paper was reviewed for this summary.
- Additional context was added by editorial staff to clarify translational relevance.
About this research
Author: Ollie Sirrell
Source: University of Reading
Contact: Ollie Sirrell – University of Reading
Image: The image is credited to Neuroscience News
Original research: Open access. “Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia” by Tatum Askey, Daniel Allen-Ross, Daniil Luzyanin, Reena Lasrado, Gary Gilmour, Stephen P. Hunt, Francesco Tamagnini, Maqsood Ahmed, Gary J. Stephens & Maria Maiarú. Communications Biology. DOI: 10.1038/s42003-026-10065-7
Abstract
Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia
Chronic pain remains a major clinical challenge because many current drugs offer limited benefit or induce tolerance and side effects. In this preclinical work, a single psilocybin dose produced a sustained anti-nociceptive effect in male and female mouse models of neuropathic pain, acting primarily through 5-HT2A receptors. Importantly, psilocybin also significantly potentiated the analgesic effect of gabapentin, offering the first preclinical evidence that a psychedelic compound can prime pain networks to increase the efficacy of an established analgesic.
This strategy could be especially relevant for the 30–50% of neuropathic pain patients who do not achieve sufficient relief from gabapentin alone. The data show that a single psilocybin injection can induce month-long changes that both directly reduce pain-like behaviours and amplify gabapentin’s later effectiveness. These findings point to a potential new therapeutic approach that leverages a brief intervention to produce sustained improvements in pain management and reduce reliance on chronic, high-risk analgesics.